Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative medicines that help patients with serious diseases. Guided by its mission to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases,” the company combines scientific research, clinical development, manufacturing, and global commercialization to address some of the world’s most challenging health conditions. Its operations span research laboratories, manufacturing facilities, and commercial organizations across numerous countries, enabling it to serve patients worldwide.
The company’s portfolio is concentrated in therapeutic areas where it believes it can deliver meaningful medical advances. These include oncology, hematology, immunology, cardiovascular diseases, and neuroscience. Bristol Myers Squibb markets several blockbuster medicines, including Opdivo, Eliquis, Revlimid, Reblozyl, Breyanzi, Camzyos, Sotyktu, and Cobenfy, while simultaneously advancing a broad pipeline of investigational therapies through clinical development. The company also collaborates with biotechnology firms and pharmaceutical partners to strengthen its research capabilities and accelerate innovation.
A key element of Bristol Myers Squibb’s strategy is balancing the performance of its established products with a rapidly growing portfolio of newer medicines. In 2025, its Growth Portfolio generated $26.4 billion in revenue, increasing 17% year over year, reflecting the company’s focus on launching innovative therapies and expanding approved indications. Looking ahead, Bristol Myers Squibb expects to deliver more than 10 new medicines and over 30 additional indications by 2030, supported by continued investment in research and development, strategic partnerships, and the use of artificial intelligence to accelerate drug discovery and clinical development.
Industry Background and the Problem
The global biopharmaceutical industry plays a critical role in addressing some of the world’s most serious and complex diseases. As populations age and life expectancy increases, the prevalence of conditions such as cancer, cardiovascular disease, autoimmune disorders, hematological diseases, and neurological illnesses continues to rise. Many of these diseases remain difficult to treat or have limited therapeutic options, creating significant unmet medical needs for patients worldwide. At the same time, healthcare systems are increasingly seeking therapies that not only improve survival but also enhance quality of life, reduce hospitalizations, and deliver long-term clinical value.
Developing innovative medicines to address these challenges is an expensive, lengthy, and highly uncertain process. Drug discovery begins with basic scientific research and progresses through preclinical studies, multiple phases of clinical trials, regulatory review, and commercialization. This process often takes more than a decade and requires billions of dollars in investment, yet many drug candidates fail during development due to safety concerns, insufficient efficacy, or regulatory hurdles. Even after receiving approval, pharmaceutical companies must continue investing in post-marketing studies, manufacturing, and commercialization while navigating evolving healthcare regulations, pricing pressures, and reimbursement policies across global markets.
The industry also faces the constant challenge of patent expirations. As patents on blockbuster medicines expire, lower-cost generic or biosimilar competitors enter the market, reducing revenue from established products. To sustain long-term growth, pharmaceutical companies must continuously replenish their portfolios by discovering new medicines, expanding approved therapies into additional disease indications, pursuing strategic acquisitions and licensing agreements, and maintaining a robust clinical pipeline. This creates an ongoing cycle of innovation where scientific breakthroughs must consistently replace aging products.
Bristol Myers Squibb believes addressing these challenges requires deep scientific expertise, sustained investment in research and development, strategic collaborations, and advanced technologies such as artificial intelligence to accelerate drug discovery and clinical development. By focusing on diseases with high unmet medical needs and building a diversified pipeline across oncology, hematology, immunology, cardiovascular disease, and neuroscience, the company aims to deliver innovative therapies that improve patient outcomes while supporting long-term business growth.
How Bristol Myers Squibb Solves the Problem
Bristol Myers Squibb addresses some of the world’s most serious diseases by combining scientific research, clinical development, advanced manufacturing, and global commercialization to develop innovative medicines. The company’s strategy focuses on discovering first-in-class and best-in-class therapies while continuously expanding approved medicines into additional disease indications. Rather than concentrating on a single therapeutic area, Bristol Myers Squibb has built a diversified portfolio spanning oncology, hematology, immunology, cardiovascular disease, and neuroscience, allowing it to address a broad range of high unmet medical needs while reducing dependence on any single product.
Oncology remains one of the company’s largest areas of focus. Bristol Myers Squibb develops therapies that harness the immune system, targeted therapies, and precision medicines to treat multiple forms of cancer. Its oncology portfolio includes Opdivo, Opdualag, Yervoy, Krazati, Abraxane, and Augtyro, which are approved across various tumor types and continue to expand through additional clinical studies and regulatory approvals. The company also invests heavily in next-generation oncology treatments aimed at improving patient outcomes and extending survival across both solid tumors and blood cancers.
In hematology, Bristol Myers Squibb has established a strong position through medicines such as Revlimid, Pomalyst, Reblozyl, Breyanzi, and Abecma, which treat multiple myeloma, lymphoma, anemia, and other blood disorders. These therapies are complemented by an active development pipeline focused on cell therapies and novel treatment approaches designed to improve outcomes for patients with difficult-to-treat hematological diseases.
The company also maintains growing franchises in immunology, cardiovascular disease, and neuroscience. Products including Sotyktu, Orencia, and Zeposia treat autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. In cardiovascular medicine, Eliquis remains one of the world’s leading oral anticoagulants, while Camzyos addresses obstructive hypertrophic cardiomyopathy and investigational therapies such as Milvexian aim to expand future treatment options. Bristol Myers Squibb is also strengthening its neuroscience portfolio through medicines such as Cobenfy for schizophrenia and continued investment in therapies targeting neurodegenerative diseases and other neurological disorders.
Innovation extends well beyond individual medicines. Bristol Myers Squibb operates an extensive global research and development organization that advances dozens of clinical programs while collaborating with biotechnology companies, academic institutions, and pharmaceutical partners to accelerate innovation. The company continuously seeks regulatory approvals for new medicines and additional indications, maximizing the value of existing therapies while expanding patient access. It also incorporates advanced technologies, including artificial intelligence and data-driven research, to improve drug discovery and clinical development efficiency. By combining scientific innovation, strategic partnerships, a diversified therapeutic portfolio, and continuous lifecycle management, Bristol Myers Squibb aims to deliver transformative medicines that improve patient outcomes while sustaining long-term growth.
Bristol Myers Squibb Business Model
Bristol Myers Squibb operates a research-driven biopharmaceutical business model focused on discovering, developing, manufacturing, and commercializing innovative prescription medicines. Rather than producing generic drugs, the company invests heavily in scientific research to develop patented therapies that address serious diseases with significant unmet medical needs. Its business model spans the entire pharmaceutical value chain—from early-stage drug discovery and clinical development to regulatory approval, manufacturing, global commercialization, and lifecycle management. This integrated approach enables Bristol Myers Squibb to generate long-term value while continuously introducing new therapies that replace products facing patent expirations.
Innovation is the foundation of the company’s business model. Bristol Myers Squibb invests billions of dollars annually in research and development (R&D) to build a diversified pipeline across oncology, hematology, immunology, cardiovascular disease, and neuroscience. Drug candidates progress through laboratory research, preclinical testing, multiple phases of clinical trials, and regulatory review before reaching patients. Beyond internal research, the company strengthens its pipeline through strategic acquisitions, licensing agreements, and collaborations with biotechnology companies, academic institutions, and pharmaceutical partners. These partnerships provide access to emerging technologies and innovative therapies while accelerating product development.
Once approved, Bristol Myers Squibb manufactures its medicines through a global production network and distributes them worldwide using an extensive commercial infrastructure. The company sells its products to wholesalers, specialty pharmacies, hospitals, healthcare providers, government agencies, and retail pharmacies across international markets. Rather than relying solely on launching new medicines, Bristol Myers Squibb also pursues lifecycle management by expanding approved therapies into additional disease indications, improving formulations, and securing regulatory approvals that extend patient access and maximize the commercial value of existing products.
Another important aspect of the business model is its focus on building a Growth Portfolio to offset revenue declines from products facing generic competition. The company continuously invests in high-growth medicines while advancing a broad clinical pipeline and acquiring innovative assets that strengthen future revenue streams. At the same time, Bristol Myers Squibb generates additional value through strategic alliances, licensing agreements, and collaborative research programs with other pharmaceutical companies. By combining continuous innovation, a diversified portfolio of patented medicines, global manufacturing and commercialization capabilities, and disciplined business development, Bristol Myers Squibb has built a scalable business model designed to deliver both improved patient outcomes and sustainable long-term growth.
How Bristol Myers Squibb Makes Money
Bristol Myers Squibb generates most of its revenue by developing, manufacturing, and selling innovative branded prescription medicines for serious diseases. Unlike generic drug manufacturers, the company focuses on patented therapies that command premium pricing because they offer meaningful clinical benefits and address significant unmet medical needs. Its medicines are sold globally through wholesalers, specialty pharmacies, hospitals, healthcare providers, government agencies, and retail pharmacies. Revenue is primarily driven by product sales, while a smaller portion comes from alliance arrangements, licensing agreements, and collaborations with pharmaceutical partners.
The company’s largest revenue source is its portfolio of marketed medicines across oncology, hematology, immunology, cardiovascular disease, and neuroscience. In 2025, Bristol Myers Squibb generated $48.2 billion in total revenue, with approximately $46.8 billion coming from product sales and around $1.4 billion from alliance and other revenues. The company’s Growth Portfolio—which consists of newer medicines early in their commercial lifecycle—generated $26.4 billion, representing 17% year-over-year growth. This portfolio has become increasingly important as older blockbuster medicines face patent expirations and generic competition.
Several blockbuster products drive Bristol Myers Squibb’s earnings. Opdivo, one of the world’s leading immuno-oncology therapies, generated approximately $10.0 billion in revenue during 2025 and remains a cornerstone of the company’s oncology business. Eliquis, developed in partnership with Pfizer, continues to be one of the world’s best-selling anticoagulants. Newer growth products are becoming increasingly important, with Reblozyl surpassing $2 billion in annual sales, while Breyanzi, Opdualag, and Camzyos each generated more than $1 billion in revenue during the year. The company also recorded the first full year of commercial sales for Cobenfy and Qvantig, both of which contributed to the expansion of its Growth Portfolio.
Beyond launching new medicines, Bristol Myers Squibb increases revenue through lifecycle management by securing regulatory approvals for additional disease indications, expanding patient populations, and improving product formulations. The company also earns revenue through strategic alliances and co-development agreements with partners such as Pfizer, Merck, BioNTech, Johnson & Johnson, and others, sharing commercialization rights, milestone payments, royalties, and development costs for selected products. These collaborations allow Bristol Myers Squibb to expand its pipeline while reducing development risk.
A significant portion of the company’s profits is reinvested into research and development to build future revenue streams. In 2025, Bristol Myers Squibb invested $14.2 billion in R&D to advance its pipeline, which management believes has the potential to deliver more than 10 new medicines and over 30 new indications by 2030. By combining blockbuster product sales, a rapidly growing portfolio of newer therapies, strategic partnerships, and continuous scientific innovation, Bristol Myers Squibb has built a business model designed to replace revenue lost from patent expirations while delivering sustainable long-term growth.
Future Outlook
Bristol Myers Squibb expects its future growth to be driven by continued innovation, a strong late-stage pipeline, and the expansion of its Growth Portfolio. The company believes it has the potential to launch more than 10 new medicines and secure over 30 additional indications by 2030, significantly expanding its presence across oncology, hematology, immunology, cardiovascular disease, and neuroscience. Management also plans to accelerate research and clinical development by leveraging artificial intelligence and digital technologies, with AI already helping reduce clinical development timelines by approximately 30%. In addition, Bristol Myers Squibb will continue investing in internal research, strategic partnerships, and business development to strengthen its pipeline and offset the impact of patent expirations. Backed by its diversified portfolio, financial flexibility, and focus on scientific innovation, the company aims to deliver sustainable long-term growth well into the 2030s while continuing to address serious diseases with high unmet medical needs.
